Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

OBJECTIVES: To describe a chemotherapy protocol combining lomustine and doxorubicin in canine histiocytic sarcoma, including outcomes and toxicity. MATERIALS AND METHODS: Retrospective review of case records for dogs with histiocytic sarcoma treated with lomustine and doxorubicin (± cyclophosphamide) alternating every 2 weeks. Data collected included signalment, clinical signs, clinicopathological abnormalities, extent of disease, response, toxicity, time to tumour progression and survival time. RESULTS: Of 17 dogs, 15 had disseminated or metastatic disease. The median number of chemotherapy cycles (one dose of each drug) received was three; most dogs discontinued therapy due to progressive disease. Dose reductions or delays occurred in 18% of cycles. The overall response rate was 58%, with a median time to tumour progression of 185 (range, 59 to 268) days for responders. The overall median survival time was 185 (18 to 402) days. No significant prognostic factors were identified. CLINICAL SIGNIFICANCE: The protocol appeared well-tolerated, had some efficacy against canine histiocytic sarcoma in the study population and could be considered as an alternative to single-agent protocols; prospective comparison may be warranted.

Original languageEnglish (US)
Pages (from-to)425-429
Number of pages5
JournalJournal of Small Animal Practice
Volume56
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Histiocytic Sarcoma
Lomustine
doxorubicin
sarcoma
Combination Drug Therapy
Doxorubicin
drug therapy
Canidae
dogs
Dogs
toxicity
therapy dogs
Drug Therapy
neoplasms
cyclophosphamide
dosage
Cyclophosphamide
Neoplasms
drugs
Pharmaceutical Preparations

Cite this

@article{718d2908f03f43dabd0f1197e9cd044f,
title = "Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma",
abstract = "OBJECTIVES: To describe a chemotherapy protocol combining lomustine and doxorubicin in canine histiocytic sarcoma, including outcomes and toxicity. MATERIALS AND METHODS: Retrospective review of case records for dogs with histiocytic sarcoma treated with lomustine and doxorubicin (± cyclophosphamide) alternating every 2 weeks. Data collected included signalment, clinical signs, clinicopathological abnormalities, extent of disease, response, toxicity, time to tumour progression and survival time. RESULTS: Of 17 dogs, 15 had disseminated or metastatic disease. The median number of chemotherapy cycles (one dose of each drug) received was three; most dogs discontinued therapy due to progressive disease. Dose reductions or delays occurred in 18{\%} of cycles. The overall response rate was 58{\%}, with a median time to tumour progression of 185 (range, 59 to 268) days for responders. The overall median survival time was 185 (18 to 402) days. No significant prognostic factors were identified. CLINICAL SIGNIFICANCE: The protocol appeared well-tolerated, had some efficacy against canine histiocytic sarcoma in the study population and could be considered as an alternative to single-agent protocols; prospective comparison may be warranted.",
author = "Cannon, {Claire M} and Borgatti, {Antonella M} and Henson, {Michael S} and Husbands, {Brian D}",
year = "2015",
month = "7",
day = "1",
doi = "10.1111/jsap.12354",
language = "English (US)",
volume = "56",
pages = "425--429",
journal = "Journal of Small Animal Practice",
issn = "0022-4510",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma

AU - Cannon, Claire M

AU - Borgatti, Antonella M

AU - Henson, Michael S

AU - Husbands, Brian D

PY - 2015/7/1

Y1 - 2015/7/1

N2 - OBJECTIVES: To describe a chemotherapy protocol combining lomustine and doxorubicin in canine histiocytic sarcoma, including outcomes and toxicity. MATERIALS AND METHODS: Retrospective review of case records for dogs with histiocytic sarcoma treated with lomustine and doxorubicin (± cyclophosphamide) alternating every 2 weeks. Data collected included signalment, clinical signs, clinicopathological abnormalities, extent of disease, response, toxicity, time to tumour progression and survival time. RESULTS: Of 17 dogs, 15 had disseminated or metastatic disease. The median number of chemotherapy cycles (one dose of each drug) received was three; most dogs discontinued therapy due to progressive disease. Dose reductions or delays occurred in 18% of cycles. The overall response rate was 58%, with a median time to tumour progression of 185 (range, 59 to 268) days for responders. The overall median survival time was 185 (18 to 402) days. No significant prognostic factors were identified. CLINICAL SIGNIFICANCE: The protocol appeared well-tolerated, had some efficacy against canine histiocytic sarcoma in the study population and could be considered as an alternative to single-agent protocols; prospective comparison may be warranted.

AB - OBJECTIVES: To describe a chemotherapy protocol combining lomustine and doxorubicin in canine histiocytic sarcoma, including outcomes and toxicity. MATERIALS AND METHODS: Retrospective review of case records for dogs with histiocytic sarcoma treated with lomustine and doxorubicin (± cyclophosphamide) alternating every 2 weeks. Data collected included signalment, clinical signs, clinicopathological abnormalities, extent of disease, response, toxicity, time to tumour progression and survival time. RESULTS: Of 17 dogs, 15 had disseminated or metastatic disease. The median number of chemotherapy cycles (one dose of each drug) received was three; most dogs discontinued therapy due to progressive disease. Dose reductions or delays occurred in 18% of cycles. The overall response rate was 58%, with a median time to tumour progression of 185 (range, 59 to 268) days for responders. The overall median survival time was 185 (18 to 402) days. No significant prognostic factors were identified. CLINICAL SIGNIFICANCE: The protocol appeared well-tolerated, had some efficacy against canine histiocytic sarcoma in the study population and could be considered as an alternative to single-agent protocols; prospective comparison may be warranted.

UR - http://www.scopus.com/inward/record.url?scp=84933676887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933676887&partnerID=8YFLogxK

U2 - 10.1111/jsap.12354

DO - 10.1111/jsap.12354

M3 - Article

VL - 56

SP - 425

EP - 429

JO - Journal of Small Animal Practice

JF - Journal of Small Animal Practice

SN - 0022-4510

IS - 7

ER -